Imagine being told you have the most aggressive form of brain cancer, glioblastoma, and facing a grueling treatment regimen that stretches for months. It's a daunting prospect, but a groundbreaking clinical trial led by WEHI is aiming to change this reality. Launched in November 2025, this national study has secured $1.49 million in funding from the Medical Research Future Fund’s National Critical Research Infrastructure – Innovative Trials scheme to explore a faster, less burdensome treatment approach.
The CONCISE trial is at the heart of this initiative, focusing on a bold idea: what if we could cut radiation therapy time by one-third without compromising effectiveness? Instead of the standard six-week course, patients would receive daily treatments over just four weeks. This shift isn’t just about saving time—it’s about giving patients more days to live life on their terms, reducing hospital stays, and easing the physical and emotional toll of treatment.
But here’s where it gets controversial: shortening treatment duration challenges decades-old protocols. Critics might argue that reducing therapy time could risk efficacy, while proponents see it as a necessary evolution in cancer care. Dr. Joseph Sia, a neuro-radiation oncologist and lead researcher, emphasizes the urgency: ‘Time is precious for our patients. If we can give them more moments with their loved ones, it’s a game-changer.’ Yet, the question remains: can we truly balance speed with safety?
The trial will involve a multidisciplinary team of experts from across Australia, including oncologists, neurosurgeons, and health economists, collaborating under the Brain Registry Australia: Innovation and TraNslation (BRAIN) platform. With plans to recruit around 330 patients, this Phase 3 randomized controlled trial is set to begin later this year in partnership with the Cooperative Trials Group for Neuro Oncology (COGNO).
And this is the part most people miss: the trial isn’t just about radiation therapy. It’s also about rethinking the entire patient experience, from treatment duration to quality of life. Supported by The Brain Cancer Centre, founded by Carrie’s Beanies 4 Brain Cancer with backing from the Victorian Government, WEHI’s Brain Cancer Research Laboratory is at the forefront of this transformative effort.
As we await the trial’s findings, one thing is clear: this research could redefine how we approach brain cancer treatment. But what do you think? Is shortening treatment time a risk worth taking, or should we stick to proven protocols? Share your thoughts in the comments—this conversation is far from over. Learn more about the trial here.
